MARS
downstream-application
MARS: downstream-application. Non-canonical antigen selection
Non-canonical antigen selection
| Kind | downstream-application |
| Deep learning | no |
| Acquisition | DDA |
| Application area | Immunopeptidomics / neoantigen |
Data
What the papers describing this method trained it on and reported its results on, as each paper states it. A version is named only where the paper names one.
Also used, purpose not recorded
- Cervical Cancer Tissue Immunopeptidomics (as deposited) · 2024 peer-reviewed
- Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8+ T cells in HIV-1 infection (as deposited) · 2022 preprint, 2024 peer-reviewed
- MS-rescue: A Computational Pipeline to Increase the Quality and Yield of Immunopeptidomics Experiments (as deposited) · 2022 preprint, 2024 peer-reviewed
- ProteomeTools (Parts I-III) · 2022 preprint, 2024 peer-reviewed
- non-canonical HLA peptides in cancer (as deposited) · 2022 preprint, 2024 peer-reviewed
Papers describing it (2)
- MARS: Improved De Novo Peptide Candidate Selection for Non-Canonical Antigen Target Discovery in Cancer (2022, Research Square, preprint)
- MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer (2024, Nature Communications, peer-reviewed)